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Objective: Comprehensive profiling of gene
expression in peripheral blood leucocytes (PBLs) in
patients with acute coronary syndrome (ACS) as a
prognosticator is needed. We explored the specific
profile of gene expression in PBLs in ACS for long-
term risk stratification.
Methods: 30 patients with ACS who underwent
primary percutaneous coronary intervention (PCI) and
15 age-matched adults who participated in medical
check-ups were enrolled from three centres. Peripheral
blood samples were collected to extract RNA for
microarray analyses.
Results: During the 5-year follow-up, 36% of this
cohort developed the expected non-fatal coronary
events (NFEs) of target lesion revascularisation (TLR)
and PCI for a de novo lesion. Class comparison
analysis (p<0.005) demonstrated that 83 genes among
7785 prefiltered genes (41 upregulated vs 42
downregulated genes) were extracted to classify the
patients according to the occurrence of NFE. Pathway
analysis based on gene ontology revealed that the
NFEs were associated with altered gene expression
regarding the T-cell receptor signalling pathway in ACS.
Univariate t test showed that the expression level of
death-associated protein kinase1 (DAPK1), known to
regulate inflammation, was the most significantly
negatively regulated gene in the event group (0.61-fold,
p<0.0005). Kaplan-Meier curve analysis and
multivariate analysis adjusted for baseline
characteristics or clinical biomarkers demonstrated that
lower DAPK1 expression in PBL emerged as an
independent risk factor for the NFEs (HR: 8.73; CI 1.05
to 72.8, p=0.045).
Conclusions: Altered gene expression in T-cell
receptor signalling in PBL in ACS could be a
prognosticator for secondary coronary events.
Trial registration number: UMIN000001932;
Results.
KEY QUESTIONS
What is already known about this subject?
▸ Previous studies have shown that serum (or
plasma) levels of cytokines or soluble proteins
derived from neutrophils, platelets during the
acute phase4 5 or at stable phase,3 after acute
coronary syndrome (ACS), are biomarkers for
predicting secondary major cardiac cardiovascu-
lar events (as well as biomarkers in stable coron-
ary artery disease to predict for primary
events6 7). Likewise, some genes and microRNAs
in peripheral blood mononuclear cells showing
specific expression profiles in ACS were demon-
strated to be potential single genetic prognostic
markers.8 9
What does this study add?
▸ We added a new insight that the altered gene
expression profile in circulating leucocytes at the
onset of ACS, particularly in the T-cell receptor
signalling pathway, can be a prognosticator of
secondary coronary events.
How might this impact on clinical practice?
▸ These findings obtained from a genetic approach
might provide new insights showing that (1)
acute response of the immune system, espe-
cially regarding T-cell receptor signalling on
ACS, varies among patients and could character-
ise their prognosis of coronary artery disease,
and (2) a set of specifically identified genes
might not only be a prognosticator but may also
provide a clue to elucidate an undetermined
genetic mechanism, called ‘residual risk’ for ath-
erosclerosis or vascular remodelling, beyond the
established risk factors such as diabetes,
smoking and low-density lipoprotein cholesterol
serum levels.
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INTRODUCTION
Acute coronary syndrome (ACS) is a major cause of
mortality worldwide. During the past decades, percutan-
eous coronary intervention (PCI) has greatly helped
improve the prognosis of patients following myocardial
infarction (MI). Restenosis post-stenting at the primary
PCI was reduced by using the latest generation of
drug-eluting stents (DESs).1 2 In addition, oral adminis-
tration of high dose of statins has been shown to reduce
the secondary cardiovascular events.3 However, resten-
osis of the intervention site still occurs after implant-
ation and the development of de novo lesions remains a
medical problem.
Atherosclerosis, which leads to MI, is a chronic inﬂam-
mation disease. Previous studies have shown that serum
(or plasma) levels of cytokines or soluble proteins
derived from neutrophils, platelets during the acute
phase4 5 or at stable phase,3 after ACS, are biomarkers
for predicting secondary major cardiac cardiovascular
events (as well as biomarkers in stable coronary artery
disease to predict for primary events6 7). Likewise, some
genes and microRNAs in peripheral blood mononuclear
cells (PBMCs) showing speciﬁc expression proﬁles in
ACS were demonstrated to be potential single genetic
prognostic markers.8 9 Recently, it has been reported
that MI accelerates the inﬂammation of atherosclerotic
plaques at a distance via extramedullary monocytopoi-
esis triggered by sympathetic nerve activation,10 indicat-
ing that peripheral immune cells may be involved in the
progression of atherosclerotic plaques after MI.
However, reﬁned prognosticating markers based on
comprehensive genetic analysis have not been estab-
lished. In this multicentre, 5-year cohort study based on
comprehensive analysis of gene expression in leucocytes
in patients with ACS, we demonstrated that altered gene
expression of peripheral blood leucocytes (PBLs) during
the acute phase of ACS could predict secondary coron-
ary events such as restenosis and new lesions.
METHODS
Study design
This prospective cohort study of the gene expression pro-
ﬁling of PBMCs in patients with cardiovascular disease
was designed to investigate gene expression proﬁles pre-
dictive of prognosis in patients with ACS and has been
registered in the UMIN Clinical Trials Registry
(UMIN000001932). This study protocol complies with
the Declaration of Helsinki, the locally appointed ethics
committee has approved the research protocol and
informed consent was obtained from each subject. This
trial included patients from three centres in Japan, from
December 2007 to November 2008. Patients were eligible
if they were admitted with acute chest pain suggestive of
ACS and intended to undergo emergency coronary angi-
ography. Patients with renal failure on haemodialysis
were excluded. Blood samples were obtained on admis-
sion before angiography. For the present study, 30
patients who had undergone primary PCI and had avail-
able peripheral blood samples for RNA collection were
included, and followed up prospectively for 5 years.
Fifteen people who underwent a medical check-up in a
different cohort study investigating metabolic diseases
were included as control participants; the institutional
review board of the Public Central Hospital of Matto
Ishikawa separately approved the protocol, and written
informed consent was obtained.
RNA collection from peripheral blood samples and
microarray analysis
Five millilitres of whole blood were collected directly
into two 2.5 mL PAXgene blood RNA tubes
(PreAnalytiX, Hombrechtikon, Switzerland) before
primary coronary angiography and were stored at −80°C
until RNA isolation. RNA was isolated from blood, using
the PAXgene system and following the manufacturer’s
instructions. Brieﬂy, PAXgene Blood RNA tubes were
centrifuged, and the pellets washed and resuspended in
buffer. Using the PAXgene Blood RNA Kit (Qiagen,
Valencia, California, USA), lysis buffer was applied to
the resuspended pellets, and RNA puriﬁcation and
extraction were performed using the columns. The
extracted RNA was stored at –80˚C until DNA microarray
analysis using 3D-Gene Human Oligo chip 25k (Toray
Industries, Inc, Tokyo, Japan), the details of which are
described in the online supplementary data section.
Follow-up
After discharge, the patients were followed up at each out-
patient clinic. Follow-up coronary angiography was sched-
uled to be performed 6 months after primary PCI in all of
the patients, whereas additional coronary angiography was
considered when cardiac ischaemia was suspected by ECG,
echocardiography, myocardial perfusion imaging, coron-
ary CTand the symptoms of the patients. The primary end
point of this study was non-fatal coronary events (NFEs),
including revascularisation of the targeted lesion (TLR) or
PCI for de novo lesions (de novo PCI).
Processing of microarray data
Hierarchical clustering of gene expression was assessed
by calculating the Pearson’s product-moment correlation
coefﬁcient, using BRB-Array Tools software (V.4.4.0)
(NCBI, NIH, Bethesda, Maryland, USA). The data were
log2-scaled, normalised, mean-centred and applied to
average linkage clustering. The resulting dendrogram
indicated the order in which the patients were grouped
based on the similarities among gene expression pat-
terns. Gene clustering data were presented graphically,
and the analysed genes were ordered by the clustering
algorithm, such that genes with the most similar expres-
sion patterns were placed adjacent to each other. To
investigate genes differentially expressed between the
groups, the class comparison tool, based on univariate t
tests, among the BRB-Array Tools, was used. To deter-
mine the gene pathways that were differentially
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expressed between the groups, 405 pathways of the
Biocarta and KEGG pathway were analysed (BRB-Array
Tools). The least squares (LS)/Kolmogorov-Smirnov
(KS) permutation test was used to identify the gene sets
with more genes differentially expressed between the
groups than expected by chance. The Efron-Tibshirani’s
test based on ‘maxmean’ statistics was also performed to
identify gene sets differentially expressed. A p value less
than 0.005 was deemed to indicate statistical signiﬁ-
cance. To classify the samples based on gene expression
proﬁles, class prediction analysis (BRB-Array Tools) was
performed using a compound covariate predictor
incorporating genes that were differentially expressed at
the p<0.01 or p<0.005 signiﬁcance level (as assessed
using the random variance t-test, using the univariate
t-test values for comparison of classes with weights). The
cross-validated misclassiﬁcation rate was computed.
Statistical analysis
Normally distributed continuous variables were pre-
sented as the mean with SD, and variables with a skewed
distribution as the median with IQR. These variables
were compared using the t test (two-tailed) and the
Mann-Whitney U-test, respectively. Categorical variables
were presented as numbers and percentages, and were
compared using the χ2 test for trends. Cumulative event
rates were estimated using the Kaplan-Meier method
and compared using the log-rank test. Univariable and
multivariable stepwise Cox proportional hazards regres-
sion models (with a p value=0.25 as a criterion to enter
a variable into the model) were used to identify inde-
pendent correlates of the 5-year outcome. All statistical
analyses were performed using SPSS statistical software
(V.19) (IBM, USA). If not prescribed, a p value less than
0.05 was considered to indicate statistical signiﬁcance.
Table 1 Baseline characteristics
Control ACS p Value
N 15 30
Age, years 64±5 65±12 0.84
Male, n (%) 13 (87) 30 (100) 0.11
Hypertension, n (%) 6 (40) 24 (80) 0.039
Diabetes mellitus, n (%) 0 (0) 15 (50) 0.001
Smoking, n (%) 3 (20) 22 (73) 0.001
STEMI (n, %) 29 (97)
Time from onset to balloon (hours) 3.7±2.9
Culprit vessel
LMT, n (%) 2 (6.7)
LAD, n (%) 13 (43.3)
LCx, n (%) 3 (10.0)
RCA, n (%) 12 (40.0)
Stent, n (%) 30 (100)
Bare metal stent, n (%) 18 (60)
Drug-eluting stent, n (%) 12 (40)
LVEF (%) 58±10
Max CK (IU/l) 2277±2116
BNP at day 7 (pg/mL) 214±342
CRP at day 0 (mg/dL) 0.6±1.3
T-Chol (mg/dL) 196 (167–202) 166 (144–203) 0.13
TG (mg/dL) 112 (87–141) 79 (59–117) 0.07
HDL-C (mg/dL) 55 (47–65) 41 (37–47) 0.001
LDL-C (mg/dL) 108 (96–123) 95 (83–125) 0.50
HbA1c, NGSP (%) 5.7 (5.6–5.9) 6.3 (5.9–7.2) 0.001
FPG (mg/dL) 96 (91–100) 113 (99–153) <0.001
FIRI (μU/mL) 4.9 (3.2–11.2) 6.4 (3.6–11.9) 0.47
HOMA-IR 1.1 (0.8–2.6) 1.8 (1.0–4.6) 0.14
BMI (kg/m2) 23.1±2.9 23.9±3.8 0.47
Medication at discharge
RAS inhibitor, n (%) 25 (83)
β blocker 6 (20)
Statins, n (%) 24 (80)
Data are shown as the mean±SD or median with IQR.
ACS, acute coronary syndrome; BMI, body mass index; BNP, brain natriuretic peptide; CK, creatine phosphokinase; FIRI, fasting
immunoreactive insulin; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; HOMA-IR,
Homeostatic Model Assessment of Insulin Resistance; LAD, left anterior descending coronary artery; LCx, left circumflex coronary artery;
LDL-C, low-density lipoprotein cholesterol; LMT, left main tract; LVEF, left ventricle ejection fraction; NGSP, National Glycohemoglobin
Standardization Program; RAS, renin-angiotensin system; RCA, right coronary artery; STEMI, ST-elevation myocardial infarction; T-chol, total
cholesterol; TG, triglyceride.




The patient cohort consisted of 30 patients with ACS
(100% males), in addition to 15 age-matched control
participants (87% males), with mean ages of 65±12 and
64±5 years, respectively. Table 1 summarises the baseline
clinical characteristics. The morbidity of diabetes in the
ACS group was 50%, and the levels of glycosylated
haemoglobin and fasting plasma glucose were higher,
and that of high-density lipoprotein cholesterol lower in
the ACS group than in the control group.
Differential gene expression profile of PBLs in patients
with ACS
As non-ﬁltered genes (24 267 genes) may include those
that are unchanged among samples, preventing efﬁcient
gene clustering due to ‘noise’, we ﬁltered out such
genes, using a different stringency method. Using 7785
ﬁltered genes (genes with a log-ratio variation in the
25th centile and >5% missing data were excluded) with
a hierarchical clustering analysis and a non-supervised
learning method, all of the participants were clustered
roughly into two groups: the ACS group and control
group (ﬁgure 1A). Among the 7785 preﬁltered genes,
class comparison analysis (p<0.0001) was used to extract
274 genes that were signiﬁcantly altered in ACS com-
pared with the control: 228 upregulated versus 46 down-
regulated genes (ﬁgure 1B and online supplementary
table S1). We examined the pathways signiﬁcantly
altered in ACS, demonstrating that 19 gene sets of the
Biocarta pathway were signiﬁcantly changed in PBLs of
patients with ACS compared with those of the control
group (table 2).
The clinical outcome at 5-year follow-up
Among 30 patients, 28 (93.3%) completed the 5-year
follow-up (tables 3 and 4). The average follow-up period
was 58±21 months. One patient died of heart failure at
11 months after the primary PCI on ACS, through a PCI
event for a de novo lesion performed 4 months before
death. NFEs occurred in 11 patients (36.6%): TLR in 7
(23.3%), de novo PCI in 7 (23.3%) and both in 4 (13.3%)
(ﬁgure 2A). In the TLR group, DES was used in four
cases (57.1%) at the primary PCI. Table 4 shows the base-
line characteristics according to the NFE. In the NFE
group, multivessel disease was signiﬁcantly predominant.
Figure 1 Hierarchical clustering analysis of 7785 genes (genes with a log-ratio variation in the 25th centile and >5% missing
data were excluded) (A) A heat map of 274 genes extracted by class comparison analysis (p<0.0001) (B) Each column
corresponds to a sample, and each row represents a gene. The gene cluster data are graphically presented as coloured images;
red and green indicate upregulated and downregulated genes, respectively. ACS, acute coronary syndrome.
4 Takashima S-ichiro, Usui S, Kurokawa K, et al. Open Heart 2016;3:e000400. doi:10.1136/openhrt-2016-000400
Open Heart
In this cohort, the levels of fasting immunoreactive
insulin and HOMA-IR were lower than those in the
control, while the rate of medication at discharge, includ-
ing RAS inhibitors and statins, and other clinical labora-
tory markers, were not different between the groups. The
serum level of low-density lipoprotein cholesterol
(LDL-C) at follow-up was not associated with the second-
ary NFEs (NFE (87±31 mg/dL) vs non NFE (100±27 mg/
dL), p=0.32). The baseline characteristics according to
the subgroup of NFE, TLR or de novo PCI are also shown
(see online supplementary tables S2-1, 2-2).
Differentially expressed genes in ACS that predict
secondary NFEs
To investigate differentially expressed genes in the NFE
group, we performed class comparison analysis
(p<0.005), extracting 83 genes among 7785 preﬁltered
genes (41 upregulated vs 42 down-regulated genes)
(ﬁgure 2B; and see online supplementary table S3).
The pathway analysis based on gene ontology revealed
that T-cell receptor signalling was the most signiﬁcantly
altered pathway in PBLs in ACS in the later NFE devel-
opment group (table 5). This gene pathway proﬁle dif-
fered from the one that showed signiﬁcant change in
ACS compared with the control (table 2). Likewise, the
gene pathway proﬁle altered in ACS in the de novo PCI
subgroup was different from that in the TLR group
(see online supplementary tables S4-1, 4-2). To assess
the predictive value of the gene sets for the NFEs, class
prediction analysis, a supervised learning method
based on the compound covariate predictor, was per-
formed using different stringencies. The rate of correct
classiﬁcation was 60–77% (see online supplementary
table S5).
DAPK1 expression levels in ACS in relation to outcome
We next investigated candidate single markers for pre-
dicting secondary NFEs. Among 83 genes extracted by
the class comparison analysis, one of the most







Pathway description Number of genes p Value p Value p Value
Biocarta pathway
HIV-I Nef: negative effector of Fas and TNF 35 *0.00001 0.00626 0.025 (+)
Keratinocyte differentiation 25 *0.00014 0.01083 0.235 (+)
Chaperones modulate interferon Signalling
pathway
11 *0.00095 0.04736 0.17 (+)
NF-κB signalling pathway 11 *0.00123 0.06918 0.115 (−)
Toll-like receptor pathway 12 *0.00139 0.11089 0.185 (−)
TNFR2 signalling pathway 12 *0.00165 0.16091 0.305 (+)
Acetylation and deacetylation of RelA in the
nucleus
10 *0.00323 0.04009 0.245 (−)
CD40L signalling pathway 9 *0.00359 0.2707 0.265 (+)
Regulation of transcriptional activity by PML 9 *0.00451 0.01201 0.375 (−)
Double-stranded RNA-induced gene expression 8 *0.00471 0.32605 0.25 (+)
IL 3 signalling pathway 10 0.00545 *0.00368 0.275 (−)
Role of ERBB2 in signal transduction and oncology 11 0.01509 *0.00022 0.49 (+)
Transcriptional activation of dbpb from mRNA 6 0.02236 *0.00221 0.41 (+)
NFAT and hypertrophy of the heart 24 0.02685 *0.00179 0.29 (−)
Fc epsilon receptor I signalling in mast cells 18 0.03265 *0.0046 0.385 (−)
Multistep regulation of transcription by Pitx2 6 0.05738 *0.0038 0.49 (+)
Growth hormone signalling pathway 12 0.06599 *0.00362 0.255 (+)
Oxidative stress-induced gene Expression Via Nrf2 8 0.11679 0.74512 *<0.005 (−)
Protein kinase A at the centrosome 7 0.90048 0.6826 *<0.005 (−)
A total of 19 of 202 investigated gene sets among the Biocarta pathways passed the 0.005 significance threshold of the LS/KS permutation
test or Efron-Tibshirani’s GSA maxmean test.
*Denotes significant p value.
ACS, acute coronary syndrome; GSA, gene set analysis; NFAT, nuclear factor of activated T-cells; NF-κB, nuclear factor-κB;
PML, promyelocytic leukemia; TNF, tumor necrosis factor.
Table 3 Outcome
Five years of follow-up achieved (n, %) 28 (93.3)
Average follow-up period (months) 58±21
MACE (n, %) 1 (3.3)
NFE (n, %) 11 (36.6)
De novo PCI (n, %) 7 (23.3)
TLR (n, %) 7 (23.3)
BMS (n, %) 3 (42.9)
DES (n, %) 4 (57.1)
Cerebral infarction (n, %) 2 (6.7)
Non-cardiac-related death (n, %) 5 (16.7)
BMS, bare-metal stents; DES, drug-eluting stents; MACE, major
adverse cardiovascular events; NFE, non-fatal coronary events;
PCI, percutaneous coronary intervention; TLR, target lesion
revascularisation.
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signiﬁcantly downregulated (with the smallest p value)
and meaningful genes in the NFE group was DAPK1
(see online supplementary table S3). Kaplan-Meier
curve analysis showed the time course of the secondary
NFEs in the three strata of the DAPK1 expression levels
on admission, demonstrating that lower DAPK1 expres-
sion in PBLs on admission in primary ACS might predict
secondary NFEs (ﬁgure 3). Multivariate analysis adjusted
for the baseline characteristics or clinical biomarkers
demonstrated that lower DAPK1 expression in PBLs
emerged as an independent risk factor for secondary
NFEs (table 6).
DISCUSSION
This is the ﬁrst study to enrol a cohort of patients with
ACS over a 5-year follow-up period in the investigation
of secondary coronary events, using DNA microarray
analysis. In this multicentre cohort study of 30 patients,
we demonstrated by comprehensive gene expression
analysis (including 24 367 genes) that altered immuno-
logical gene expression in peripheral leucocytes at the
onset of ACS, particularly genes involved in the T-cell
receptor signalling pathway, could be useful for classify-
ing patients according to the risk of secondary coronary
events.
In all of the patients with ACS evaluated, the gene
expression proﬁle in PBLs was apparently different from
that of the control participants from the medical
check-up. The pathway signiﬁcantly altered in patients
with ACS included the Toll-like receptor pathway and
CD40 ligand signalling pathway (table 2), ﬁndings that
were comparable to those of previous reports.11 12 Since
the patients were included during the period 2007–
2008, when bare metal stents or the ﬁrst generation of
DES, the Cypher or Taxus stent, were used for primary
PCI for ACS in Japan, 30% of patients were estimated to
develop in-stent restenosis at the 6-month follow-up. In
Table 4 Baseline characteristics according to outcome
NFE
Yes (N=11) No (N=19) p Value
Age, years 66±10 64±14 0.66
Male, n (%) 11 (100) 19 (100)
Hypertension, n (%) 10 (91) 14 (74) 0.37
Diabetes mellitus, n (%) 7 (64) 8 (42) 0.45
Smoking, n (%) 9 (82) 13 (68) 0.67
Number of diseased vessels, n 0.01
1 vessel 0 10
2 vessels 8 6
3 vessels 3 3
LMT lesion 2 (18) 3 (16) 1.00
Stent
Bare metal stent, n 5 13 0.26
Drug-eluting stent, n 6 6
LVEF (%) 63±10 54±12 0.24
Max CK (IU/L) 1488 (765–1940) 2188 (1298–3201) 0.12
BNP at day 7 (pg/mL) 102 (72–370) 48 (33–103) 0.11
CCr (mL/min) 62 (56–70) 83 (52–116) 0.29
hsCRP at day 0 (mg/dL) 0.18 (0.06–0.53) 0.17 (0.09–0.32) 0.76
T-Chol (mg/dL) 174 (145–207) 158 (144–198) 0.76
TG (mg/dL) 74 (69–129) 79 (57–110) 0.70
HDL-C (mg/dL) 42 (37–48) 40 (38–45) 0.78
LDL-C (mg/dL) 91 (82–121) 95 (85–125) 0.95
HbA1c, NGSP (%) 6.4 (6.2–6.8) 6.1 (5.8–7.5) 0.56
FPG (mg/dL) 108 (101–121) 116 (99–156) 0.53
FIRI (μU/mL) 3.5 (2.5–6.1) 9.0 (4.5–16.4) 0.011
HOMA-IR 0.76 (0.66–1.52) 2.90 (1.10–6.27) 0.001
Lp(a) (mg/dL) 37 (32–45) 26 (13–42) 0.27
BMI (kg/m2) 23.3±3.9 24.2±3.5 0.53
Medication at discharge
RAS inhibitor, n (%) 8 (73) 16 (84) 0.64
Statins, n (%) 8 (73) 16 (84) 0.64
Data are shown as the mean±SD or median with IQR.
BMI, body mass index; BNP, brain natriuretic peptide; CCr, creatinine clearance (calculated using the Cockcroft and Gault formula); FIRI,
fasting immunoreactive insulin; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, Homeostatic Model
Assessment of Insulin Resistance; hsCRP, high sensitivity C reactive protein; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein (a);
NFE, non-fatal coronary event; LMT, left main tract; LVEF, left ventricle ejection fraction; RAS, renin-angiotensin system; T-chol, total
cholesterol; TG, triglyceride.
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this cohort, 36% of participants were subjected to TLR
and/or de novo PCI, regardless of the serum level of
LDL-C at the follow-up. Interestingly, the gene sets that
were signiﬁcantly altered in the group that developed
secondary coronary events, including TLR or de novo
PCI, during the follow-up, were quite different from the
gene groups that changed substantially during the acute
phase of ACS. Pathway analysis based on gene ontology
demonstrated that altered gene expression associated
with T-cell receptor signalling in ACS was a risk for sec-
ondary NFEs (table 5).
Many studies have been performed in pursuit of a new
single prognosticator in peripheral blood samples. The
plasma concentrations of myeloperoxidase (MPO),4 13
soluble CD40 ligand (sCD40L)12 and combination of
established prognostic biomarkers, such as BNP, highly
sensitive C reactive protein or cardiac troponin I,5 have
been reported to be associated with the risk of death or
recurrent ischaemic events, as well as ﬁrst cardiovascular
events.6 7 Because MPO or CD40L is released from neu-
trophils or activated platelets, both of which are key
pathophysiological cells in ACS, it might be reasonable
to focus on those molecules as candidate biomarkers for
recurrent ischaemic events. Nakayama et al14 reported
class A macrophage scavenger receptor (SR-A) as a pre-
dictive marker for a repeated cardiovascular event. They
utilised a gene chip microarray system in patients with
ACS for comprehensive analysis of gene expression in
PBMCs. However, the study was performed on a small
scale and was only aimed at extracting the genes most
increased or decreased in ACS among a prespeciﬁed
gene subset. Considering the mechanistic difference in
occurrence between ACS (acute inﬂammation by neu-
trophil and thrombosis) and the secondary coronary
events, including TLR or de novo PCI (chronic inﬂam-
mation by lymphocytes or monocytes), the key factors
for the risk prediction of secondary coronary events are
not necessarily the same as the prime players in ACS. In
fact, in this cohort study, SR-A was not identiﬁed as a
gene predicting secondary coronary events. In a larger
scale of patients with ACS, Ruparelia et al15 recently
demonstrated that the differential gene expression
proﬁle of PBMC—but not PBL—at the onset of ACS,
using DNA microarray analysis, made a striking contrast
Figure 2 A Kaplan-Meier curve showing the cumulative incidence of the secondary NFE of TLR or de novo PCI during the
5-year follow-up (30 patients) (A) A heat map of 83 genes that were extracted among 7785 prefiltered genes by class comparison
analysis (p<0.005) (B) Each column corresponds to a sample, which was classified according to the secondary NFE group,
including TLR or de novo PCI (right side) and no event group (light side). The gene cluster data are graphically presented as
coloured images: red and green indicate upregulated and downregulated genes, respectively; grey denotes unavailable data. An
asterisk indicates DAPK1 as the most significantly altered and meaningful gene, of which expression was highlighted in yellow.
DAPK1, death-associated protein kinase1; NFE, non-fatal coronary events; PCI, percutaneous coronary intervention; TLR, target
lesion revascularisation.
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to patients with stable ischaemic coronary disease, pro-
viding speciﬁc therapeutic targeting of key genes that
could be useful for protecting acute myocardial
damages. Different from these previous studies, we ﬁrst
utilised the gene expression proﬁling on ACS for pre-
dicting the secondary events. Since the progression of
coronary atherosclerotic lesion or plaque instability
post-ACS is associated with multiple factors including
inﬂammation, and the risk stratiﬁcation still remains
fully elucidated, the approach using comprehensive
gene expression may provide a new insight into a spe-
ciﬁc signiﬁcant function in leucocytes, for vascular
remodelling, as well as providing a prognosticator of sec-
ondary events.
DAPK is an actin-ﬁlament-associated, calcium
calmodulin-dependent, serine/threonine kinase that pri-
marily promotes apoptosis to various stimuli, including







Pathway description Number of genes p Value p Value p Value
Biocarta
T-cell receptor signalling pathway 26 *0.00001 *0.00001 0.25 (+)
Fc epsilon receptor I signalling in mast cells 18 *0.00005 *0.00097 0.105 (+)
Lck and Fyn tyrosine kinases in the initiation of TCR
Activation
9 *0.00006 *0.00168 0.37 (−)
BCR signalling pathway 15 *0.00009 *0.00325 0.42 (+)
The co-stimulated signal during T-cell activation 11 *0.00019 0.0119 0.26 (−)
Nerve growth factor pathway 11 *0.00027 0.04891 0.29 (+)
Phosphoinositides and their downstream targets 11 *0.00048 0.02979 0.36 (+)
Activation of Csk by cAMP-dependent protein
kinase inhibits signalling through the T-cell receptor
14 *0.00049 0.01546 0.435 (+)
Granzyme A-mediated apoptosis pathway 7 *0.00052 *0.0002 0.435 (+)
Role of Tob in T-cell activation 10 *0.00223 *0.00365 0.495 (+)
Ras-independent pathway in NK cell-mediated
Cytotoxicity
12 *0.00227 *0.00075 0.345 (−)
HIV-induced T-cell apoptosis 5 *0.00305 0.01715 0.495 (+)
Mechanism of gene regulation by peroxisome
Proliferators via PPARα
28 *0.00379 0.10998 0.105 (+)
Links between Pyk2 and MAP kinases 14 *0.00415 0.03066 0.385 (+)
Angiotensin II-mediated activation of the JNK
pathway via Pyk2-dependent Signalling
10 *0.00454 0.0191 0.21 (−)
KEGG
T-cell receptor signalling pathway 57 *0.00001 *0.00036 0.125 (+)
Primary immunodeficiency 20 *0.00001 *0.00177 0.375 (+)
Natural killer cell-mediated cytotoxicity 54 *0.00003 *0.00086 0.12 (+)
Chemokine signalling pathway 78 *0.00081 0.01394 0.06 (−)
Fc epsilon RI signalling pathway 32 *0.00219 0.03961 0.025 (−)
B-cell receptor signalling pathway 38 *0.00262 0.03951 0.515 (+)
Pyrimidine metabolism 45 *0.00416 0.06912 0.185 (−)
Pentose phosphate pathway 14 *0.00471 0.16112 0.48 (+)
Amino sugar and nucleotide sugar metabolism 20 0.00903 *0.00303 0.285 (−)
Glyoxylate and dicarboxylate metabolism 7 0.05672 *0.00454 0.175 (−)
Ribosome 77 0.3271 *0.00405 0.29 (+)
A total of 15 of 202 and 11 of 203 investigated gene sets among the Biocarta and KEGG pathways, respectively, passed the 0.005
significance threshold of the LS/KS permutation test or Efron-Tibshirani’s GSA maxmean test.
*Denotes significant p value.
BCR, B-cell receptor; NFE, non-fatal coronary event; NK, natural killer; TCR, T-cell receptor.
Figure 3 Kaplan-Meier curves showing the cumulative
incidence of the secondary NFE of TLR or de novo PCI
during the 5-year follow-up, according to the baseline
expression level of DAPK1 in peripheral blood leucocytes
(30 patients). DAPK1, death-associated protein kinase1; NFE,
non-fatal coronary events; PCI, percutaneous coronary
intervention; TLR, target lesion revascularisation.
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Fas, INF-γ and TNF-α,16 in various cell types.17 In
human carotid endarterectomy specimens, DAPK has
been demonstrated substantially to express in the ath-
erosclerotic plaque (foam cells of smooth muscle
cells).18 On the other hand, DAPK has also been
reported to exert antiapoptotic functions in different
situations, as it was shown to suppress TNF α-induced
apoptosis by shear stress in endothelial cells.19 Lai and
Chen20 demonstrated that DAPK negatively regulates
T-cell activation by selective inhibition in T-cell receptor-
triggered NF-κB activation.21 Furthermore, in an acute
T-cell leukaemia cell line, silencing of DAPK resulted in
reduced susceptibility to Fas-induced apoptosis.22 These
together may evoke a hypothesis that DAPK in circulat-
ing T-cells and endothelial cells protectively acts against
vascular remodelling. In this study, DAPK1 was one of
the most signiﬁcantly suppressed genes in PBLs in ACS
in the subgroups subsequently enduring TLR or de novo
PCI. A genetic approach could enable speculation that
the relatively low-expressed genes, such as DAPK1, at the
onset of ACS in the subgroup of worse coronary progno-
sis, are essential for repair of diseased arterial endothe-
lium but run out and poor to be recruited. These
factors indicate that DAPK1 could be a candidate
marker for prediction of secondary coronary events as
well as being a therapeutic target.
Limitations
The limitations of this study must be recognised prior to
its interpretation. First, not all of the patients underwent
follow-up CAG, due to non-agreement by the patient or
a hospital change in eight patients, all of whom were
assigned to the group with no event. However, even after
excluding these eight patients from the analysis, T-cell
receptor signalling remained the principal pathway to
be signiﬁcantly altered on admission in patients with
subsequent secondary coronary events. Second, the deci-
sion to perform TLR or de novo PCI was left to the dis-
cretion of the physician in charge. Third, this cohort,
being started in 2007 or 2008, was rather old, so the fre-
quency of use of bare metal stents for primary PCI was
high (60%), and the remaining DESs were ﬁrst gener-
ation, a ﬁnding different from that observed currently.
Fourth, the correct prediction rate as assessed by the
class prediction analysis based on the combination of sig-
niﬁcantly altered gene sets was not satisfactory. This may
be partially attributed to insufﬁcient study data setting to
control a false discovery rate with an appropriately low p
value. Additional studies are needed to reﬁne the pre-
diction models. Finally, the expression level of DAPK1 in
PBLs was evaluated only by a microarray from a small
sized study sample as clinical outcome data, possibly
causing a large variation in the results. Therefore,
DAPK1 expression should be validated in another
large-scaled prospective study, using quantitative reverse
transcription polymerase chain reaction (qRT-PCR).
CONCLUSIONS
In this current multicentre, 5-year cohort study using
comprehensive gene expression analysis, we demon-
strated that the altered gene expression proﬁle in circu-
lating leucocytes at the onset of ACS, particularly in the
T-cell receptor signalling pathway, can be a prognostica-
tor of secondary coronary events. This ﬁnding may
provide new insight regarding an undetermined genetic
mechanism, called ‘residual risk’ for atherosclerosis or
vascular remodelling, beyond the established risk factors
such as diabetes, smoking and LDL-C serum levels.
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Table 6 Unadjusted and adjusted HRs for the 5-year NFE group
NFE
HR (95% CI) p Value
Univariable (unadjusted) Cox model
Multivessel disease (disease in 2 or 3 vessels) 43.5 (0.260 to 7271) 0.150
Fasting IRI (>10 μU/mL) 0.025 (0.000 to 11.1) 0.236
Diabetes 2.23 (0.650 to 7.62) 0.203
Low-DAPK1 (<median) 11.3 (1.42 to 89.6) 0.022
Multivariable (adjusted) Cox model
Low-DAPK1 (<median) 8.73 (1.05 to 72.8) 0.045
DAPK1, death-associated protein kinase1; IRI, immunoreactive insulin; NFE, non-fatal coronary event.
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